sacituzumab govitecan-hziy
8 abstracts
Abstract
Novel protein drug conjugate ANXV-chemo and cytotoxic and anti-proliferative effects against human triple-negative breast cancer in vitro.Org: Annexin Pharmaceuticals AB (publ), Truly Labs AB, ALMIR Conseil,
Abstract
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, UNC Lineberger Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Emory University Hospital,
Abstract
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.Org: Davis Comprehensive Cancer Center, Swog Gu Bladder Patient Advocate,
Abstract
Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling.Org: mProbe Inc., Stanford University School of Medicine,
Abstract
Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.Org: Department of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine, The University of Arkansas for Medical Sciences/Arkansas Children’s Hospital,